A simple computer program for guiding management of cardiovascular risk factors and prescribing

British Medical Journal

Volumn 318, Issue 7176, 1999, Pages 101-105

  Hingorani, Aroon D ^a,b   Vallance, Patrick ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Department of Clinical Pharmacology and Therapeutics ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; COMPUTER PROGRAM; HEALTH CARE COST; HEART INFARCTION; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

EID: 0033537323     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7176.101     Document Type: Article

References (24)

1. Dawber TR. The Framingham study. The epidemiology of atherosclerotic disease. Cambridge, MA: Harvard University Press, 1980.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7.
5. Jackson R, Beaglehole R. Evidence-based management of dyslipidaemia. Lancet 1995;344:1440-1.
6. Haq U, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995;346:1467-71. (Correction. Lancet 1996;348:1251-2.)
7. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin CM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary heart disease: an updated Sheffield table. Lancet 1996;348:387-8.
8. Jackson R, Barham P, Bills J, McLennan S, Macmahon S, Maling T. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107-10.
9. Pyorala K, De Backer G, Graham I, Poole-Wilson P. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-1.
10. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990;121:293-8.
11. Anderson KM, Wilson PWT, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
12. Wolf PA, D'Agostino RB, Blanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 1991;22:312-8.
13. Winyard G. SMAC statement on the use of statins. London: Department of Health, 1997. (EL(97)41 HCD 750 IP Aug 97).
14. Collins R, Peto R, Macmahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
15. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly programme (SHEP). JAMA 1991;265:3255-64.
16. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
17. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406-16.
18. Haq IU, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for the prevention of coronary heart disease: what policy now? Clin Sci 1996;91:399-413.
19. Fremantle N, Barbour R, Johnson R, Marchment M, Kennedy A. The use of statins: a case of misleading priorities? BMJ 1997;315:826-8.
20. Muldoon MF, Criqui MH. The emerging role of statins in the prevention of coronary heart disease. BMJ 1997;315:1554-5.
21. Skolbekken J-A. Communicating the risk reduction achieved by cholesterol reducing drugs. BMJ 1998;316:1956-8.
22. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation 1998;97:1440-5.
23. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1991;308:367-73.
24. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 1998;97:946-52.